

# CITATION REPORT

List of articles citing

Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes

DOI: 10.1016/j.exphem.2009.01.010

Experimental Hematology, 2009, 37, 616-628.e2.

**Source:** <https://exaly.com/paper-pdf/46560267/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF | Citations |
|-----|--|----|-----------|
| 115 | Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. <b>2010</b> , 95, 1579-86          |    | 55        |
| 114 | Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. <b>2010</b> , 95, 2144-52        |    | 84        |
| 113 | Thymoglobulin, interferon- $\gamma$ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. <b>2010</b> , 8, 129                                      |    | 35        |
| 112 | Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. <b>2010</b> , 16, 1603-7   |    | 46        |
| 111 | In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. <b>2011</b> , 34, 469-79  |    | 16        |
| 110 | Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. <b>2011</b> , 118, 3301-10                            |    | 153       |
| 109 | Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <b>2011</b> , 117, 510-8                                |    | 49        |
| 108 | Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction. <b>2011</b> , 12, 393-400               |    | 6         |
| 107 | Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy. <b>2011</b> , 3, 3661-75   |    | 7         |
| 106 | The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. <b>2011</b> , 2011, 649359                              |    | 14        |
| 105 | IL-7R $\alpha$ low memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus. <b>2012</b> , 51, 1587-94   |    | 18        |
| 104 | Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. <b>2012</b> , 2012, 238924                                      |    | 36        |
| 103 | Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. <b>2012</b> , 2012, 473245  |    | 21        |
| 102 | Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. <b>2012</b> , 35, 579-86             |    | 20        |
| 101 | NK-cells have an impaired response to acute exercise and a lower expression of the inhibitory receptors KLRG1 and CD158a in humans with latent cytomegalovirus infection. <b>2012</b> , 26, 177-86 |    | 26        |
| 100 | A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use. <b>2012</b> , 49, 159-65                      |    | 10        |
| 99  | Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. <b>2012</b> , 12, 673-84   |    | 107       |

|    |   |     |     |
|----|---|-----|-----|
| 98 | Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model. <b>2012</b> , 12, 247-52  |     | 6   |
| 97 | Increased numbers but functional defects of CD56+CD3+ cells in lung cancer. <b>2012</b> , 24, 409-15  |     | 20  |
| 96 | The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. <i>Cytotherapy</i> , <b>2012</b> , 14, 91-103  | 4.8 | 72  |
| 95 | Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. <b>2013</b> , 155, 27-30   |     | 29  |
| 94 | Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". <b>2013</b> , 21, 2268-77  |     | 71  |
| 93 | Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. <b>2013</b> , 32, 553-60   |     | 3   |
| 92 | Increased numbers and functional activity of CD56+ T cells in healthy cytomegalovirus positive subjects. <b>2014</b> , 142, 258-68  |     | 30  |
| 91 | Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. <i>Experimental Hematology</i> , <b>2014</b> , 42, 1013-21.e1   | 3.1 | 20  |
| 90 | Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. <b>2014</b> , 37, 448-60  |     | 36  |
| 89 | SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy. <b>2014</b> , 2, 75  |     | 11  |
| 88 | Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. <b>2014</b> , 2014, 897214  |     | 30  |
| 87 | Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. <i>Cytotherapy</i> , <b>2014</b> , 16, 835-44 | 4.8 | 16  |
| 86 | Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells. <b>2014</b> , 86, 257-62   |     | 3   |
| 85 | Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines. <i>Cytotherapy</i> , <b>2014</b> , 16, 845-56                          | 4.8 | 14  |
| 84 | Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. <b>2014</b> , 28, 1596-605  |     | 193 |
| 83 | Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. <b>2014</b> , 134, 342-51   |     | 68  |
| 82 | Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma. <b>2014</b> , 37, 559-66   |     | 11  |
| 81 | Can the dual-functional capability of CIK cells be used to improve antitumor effects?. <b>2014</b> , 287, 18-22   |     | 23  |

|    |  |        |
|----|--|--------|
| 80 | An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. <b>2014</b> , 14, 905-16   | 47     |
| 79 | Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells. <b>2015</b> , 14, 3082-9  | 5      |
| 78 | Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. <b>2015</b> , 15, 58-65  | 11     |
| 77 | Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus. <i>Cytotherapy</i> , <b>2015</b> , 17, 1139-51   | 4.8 15 |
| 76 | Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia. <b>2015</b> , 9, 535-541   | 13     |
| 75 | Cytokine-induced killer (CIK) cells: from basic research to clinical translation. <b>2015</b> , 34, 99-107   | 37     |
| 74 | Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition. <b>2015</b> , 26, 220-31                      | 13     |
| 73 | Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. <b>2015</b> , 7, 999-1010  | 21     |
| 72 | Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation. <b>2015</b> , 69, 18-23  | 12     |
| 71 | Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). <b>2015</b> , 141, 839-49   | 98     |
| 70 | The dual-functional capability of cytokine-induced killer cells and application in tumor immunology. <b>2015</b> , 76, 385-91  | 17     |
| 69 | Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells. <b>2016</b> , 16, 99-108  | 18     |
| 68 | Convergence of Innate and Adaptive Immunity during Human Aging. <b>2016</b> , 7, 445   | 59     |
| 67 | Immune phenotypes predict survival in patients with glioblastoma multiforme. <b>2016</b> , 9, 77   | 42     |
| 66 | Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT Cells. <b>2016</b> , 11, e0151535 | 21     |
| 65 | Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma. <b>2016</b> , 13, 2645-54  | 2      |
| 64 | Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. <b>2016</b> , 77, 1239-1247  | 7      |
| 63 | Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells. <b>2016</b> , 63, 2230-2239  | 11     |

|    |   |        |
|----|---|--------|
| 62 | Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. <b>2016</b> , 5, e1199311  | 15     |
| 61 | Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy. <b>2016</b> , 6, 35314  | 20     |
| 60 | Effects of CIK on hypoxia inducible factor-1 $\alpha$ and T-cell subsets on colon 26 cancer xenograft mice. <b>2016</b> , 11, 1371-1374   | 4      |
| 59 | Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. <b>2016</b> , 65, 525-36   | 42     |
| 58 | Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. <b>2017</b> , 36, 99-105   | 26     |
| 57 | Modification of cytokine-induced killer cells with folate receptor alpha (FR $\alpha$ )-specific chimeric antigen receptors enhances their antitumor immunity toward FR $\alpha$ -positive ovarian cancers. <b>2017</b> , 85, 293-304 | 19     |
| 56 | Comparative investigation of the effects of specific antigen-sensitized DC-CIK and DC-CTL cells against B16 melanoma tumor cells. <b>2017</b> , 15, 1533-1538   | 2      |
| 55 | Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2017</b> , 23, 2070-2078                      | 35     |
| 54 | CIK as therapeutic agents against tumors. <b>2017</b> , 85, 32-44   | 30     |
| 53 | 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells. <b>2017</b> , 7, 4859  | 17     |
| 52 | Cancer Immunotherapy with Cytokine-Induced Killer Cells. <b>2017</b> , 12, 289-299  | 23     |
| 51 | The Combined Antitumor Effects of I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model. <b>2017</b> , 16, 1083-1091                                    | 2      |
| 50 | Immune-Mediated Therapies for Liver Cancer. <b>2017</b> , 8,  | 17     |
| 49 | Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion. <b>2017</b> , 12, e0175704   | 2      |
| 48 | Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. <b>2017</b> , 12, e0182002   | 43     |
| 47 | Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. <b>2017</b> , 23, 235-246  | 9      |
| 46 | Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. <b>2018</b> , 9, 196   | 9      |
| 45 | Innovative Clinical Perspectives for CIK Cells in Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,   | 6.3 28 |

|    |  |     |    |
|----|--|-----|----|
| 44 | Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19 tumors. <i>Cytotherapy</i> , <b>2018</b> , 20, 1077-1088          | 4.8 | 3  |
| 43 | Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20, | 6.3 | 16 |
| 42 | CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,   | 6.3 | 24 |
| 41 | Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <b>2019</b> , 19, 523                  |     | 10 |
| 40 | Cellular therapy for acute myeloid Leukemia - Current status and future prospects. <b>2019</b> , 37, 100578  |     | 28 |
| 39 | Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. <b>2019</b> , 25, 1281-1292                                      |     | 17 |
| 38 | Enhanced metabolic activities for ATP production and elevated metabolic flux via pentose phosphate pathway contribute for better CIK cells expansion. <b>2019</b> , 52, e12594   |     | 5  |
| 37 | Cancer Biology and Advances in Treatment. <b>2020</b> ,  |     | 0  |
| 36 | A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks. <i>Cytotherapy</i> , <b>2020</b> , 22, 511-518       | 4.8 | 1  |
| 35 | Presence of the Transmembrane Protein Neuropilin in Cytokine-induced Killer Cells. <b>2020</b> , 40, 5489-5496   |     |    |
| 34 | P09.01 Adoptive cell therapy of hematological malignancies using cytokine-induced killer cells retargeted with monoclonal antibodies. <b>2020</b> , 8, A51.2-A52                 |     |    |
| 33 | P09.02 Mapping and tackling tumor and chemotherapy-induced immune suppression in breast cancer sentinel lymph nodes. <b>2020</b> , 8, A52-A53                                    |     |    |
| 32 | CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <b>2020</b> , 26, 6321-6334                                  |     | 5  |
| 31 | Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. <b>2020</b> , 235, 9291-9303   |     | 20 |
| 30 | Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma. <b>2020</b> , 82, 106351   |     | 7  |
| 29 | Dendritic cell therapy in cancer treatment; the state-of-the-art. <b>2020</b> , 254, 117580  |     | 37 |
| 28 | A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer. <b>2021</b> , 23, 265-274   |     | 23 |
| 27 | Prediction of clinical prognosis in cutaneous melanoma using an immune-related gene pair signature. <b>2021</b> , 12, 1803-1812  |     | 3  |

|    |   |     |    |
|----|---|-----|----|
| 26 | Surface NKG2C Identifies Differentiated $\gamma\delta$ -Cell Clones Expanded in Peripheral Blood. <b>2020</b> , 11, 613882  |     | 4  |
| 25 | Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. <b>2021</b> , 10,  |     | 2  |
| 24 | Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. <b>2021</b> , 10, 2091-2102 |     | 1  |
| 23 | Induction of T Cell Senescence by Cytokine Induced Bystander Activation. <b>2021</b> , 2,   |     | 1  |
| 22 | Mixed adenoneuroendocrine carcinomas of stomach and ampulla of vater after curative-intent resection: a single center cases series. <b>2021</b> , 21, 329   |     | 0  |
| 21 | BL-01, an Fc-bearing, tetravalent CD20 $\times$ CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo. <i>Cytotherapy</i> , <b>2021</b> ,  | 4.8 |    |
| 20 | The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. <b>2021</b> , 10,  |     | 6  |
| 19 | The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. <b>2021</b> ,  |     | 1  |
| 18 | Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. <b>2020</b> , 1292, 113-130   |     | 2  |
| 17 | Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. <b>2018</b> , 24, 1839-1858  |     | 20 |
| 16 | IL12 integrated into the CAR exodomain converts CD8 T $\gamma\delta$ cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. <b>2021</b> ,   |     | 3  |
| 15 | Generation and Gene Expression of CD28 $\times$ CD8 T Cells in Human. <b>2018</b> , 1-19  |     |    |
| 14 | Generation and Gene Expression of CD28 $\times$ CD8 T Cells in Human. <b>2019</b> , 553-571   |     |    |
| 13 | Novel Immunotherapeutic Approach in Gastric Cancer. <i>Acta Medica Bulgarica</i> , <b>2020</b> , 47, 47-54  | 0.2 | 0  |
| 12 | Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 7728-36             |     | 13 |
| 11 | The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset. <i>Blood Transfusion</i> , <b>2017</b> , 15, 93-100                                    | 3.6 | 2  |
| 10 | Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,   | 6.3 | 2  |
| 9  | Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use.. <i>Cytotherapy</i> , <b>2022</b> ,  | 4.8 | 0  |

|   |  |     |   |
|---|--|-----|---|
| 8 | Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer.. <i>Cell Communication and Signaling</i> , <b>2022</b> , 20, 41                       | 7.5 | ○ |
| 7 | Comparison of cytotoxic potency between freshly cultured and freshly thawed cytokine-induced killer cells from human umbilical cord blood. <i>Cell and Tissue Banking</i> ,  | 2.2 |   |
| 6 | Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells. 13,                 |     | ○ |
| 5 | Changes in the TCR repertoire of T-cell subsets during culture of cytokine-induced killer cells.   |     | ○ |
| 4 | Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma. <b>2023</b> , 18, e0280023                              |     | ○ |
| 3 | Adoptive Cell Transfer for Solid Tumors. <b>2023</b> ,   |     | ○ |
| 2 | Manufacturing and Treatment Standardization of Tumor Associated Antigen Stimulated Autologous Dendritic and Cytokine Induced Killer Cell Coculture for Cancer Immunotherapy. |     | ○ |
| 1 | Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer. <b>2022</b> , 51, 1251-1257                           |     | ○ |